Importantly, while the METY1230S mutation has been previously identified in patients and pre‐clinically characterised,24, 33 this is the first time that the clinical activity of a type II MET inhibitor against a tumour harbouring this MET alteration is reported. The gene discussed is MET; the disease is neoplasm.